Immunohistochemistry for phosphorylated ERK1/2 (p-ERK) was predictive of OS in recurrent GBM patients treated with adjuvant PD-1 inhibition in two separate independent patient cohorts. This evidence concerns the gene MAPK3 and glioblastoma.